ICON plc sets Q2 2026 earnings call for July 30
ICON plc plans to release financial results for the second quarter 2026 after the market closes on Wednesday, July 29, 2026.
Rhea-AI Filing Summary
ICON plc plans to release financial results for the second quarter 2026 after the market closes on Wednesday, July 29, 2026. A conference call and webcast to discuss the results and business performance is scheduled for Thursday, July 30, 2026 at 8:00am ET, with a replay available about one hour after the call.
ICON is described as a world-leading clinical research organization providing consulting, clinical development, commercialization and post-marketing solutions to life sciences and public health customers globally. As of March 31, 2026, it employed approximately 40,350 people across 97 locations in 55 countries. The company includes forward-looking statements language outlining risks such as reliance on pharmaceutical clients, industry competition, execution of projects, regulatory changes, exchange-rate movements, inflation and rising labor costs.
Positive
- None.
Negative
- None.
Key Figures
Q2 2026 results release date: July 29, 2026
Earnings call date and time: July 30, 2026 8:00am ET
Employees: 40,350 employees
+2 more
5 metrics
Q2 2026 results release date
July 29, 2026
Financial results for the second quarter 2026 will be released after market close on this date.
Earnings call date and time
July 30, 2026 8:00am ET
Scheduled conference call and webcast to discuss second quarter 2026 results.
Employees
40,350 employees
Approximate number of employees as of March 31, 2026.
Global locations
97 locations
Number of locations worldwide as of March 31, 2026.
Countries of operation
55 countries
Countries in which ICON operated as of March 31, 2026.
Key Terms
forward-looking statements, safe harbor provisions, clinical research organization, contracted revenue, +1 more
5 terms
forward-looking statements regulatory
"Statements included herein which are not historical facts are forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
safe harbor provisions regulatory
"Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995."
Safe harbor provisions are rules or legal protections that shield companies or individuals from certain penalties or liabilities when they follow specific guidelines or procedures. They provide a sense of security, encouraging compliance and innovation by reducing the fear of legal repercussions if they act in good faith. For investors, these provisions help ensure that companies are transparent and accountable without the risk of unfair punishment for honest mistakes.
clinical research organization medical
"ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced..."
A clinical research organization (CRO) is a company that manages and runs human studies for medicines, medical devices and diagnostics on behalf of developers and sponsors. Think of a CRO as an outsourced project manager and contractor for testing — they recruit patients, collect data, handle regulatory paperwork and keep studies on schedule. Investors watch CROs because their quality and capacity affect development speed, cost and regulatory risk, which in turn influence when and whether products reach the market.
contracted revenue financial
"Examples of forward-looking statements include, but are not limited to, statements regarding the following: contracted revenue;"
Contracted revenue is the amount of money a business expects to receive because customers have signed binding agreements for goods or services over a set period. For investors it shows how much future cash is already promised, reducing uncertainty about sales — like having customers hand you a schedule of payments in advance — which helps assess growth potential, valuation and risk compared with one-off or uncertain sales.
post-marketing solutions medical
"we deliver integrated consulting, clinical development, commercialization and post-marketing solutions..."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will ICON plc (ICLR) release its second quarter 2026 financial results?
ICON plc will release its second quarter 2026 financial results after the market closes on Wednesday, July 29, 2026. These results will then be discussed on a conference call and webcast the following morning.
When is ICON plc’s (ICLR) Q2 2026 earnings conference call and how can it be accessed?
The Q2 2026 earnings call is scheduled for Thursday, July 30, 2026 at 8:00am ET. Access details and links to the live webcast and replay will be posted in the Investor section of ICON’s website under “Events”.
What kind of business is ICON plc (ICLR) and whom does it serve?
ICON plc is a world-leading clinical research organization. It provides consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide, supporting therapies from molecule to medicine.
How large is ICON plc (ICLR) in terms of employees and global presence?
As of March 31, 2026, ICON employed approximately 40,350 people across 97 locations in 55 countries. This footprint reflects a broad international presence serving life sciences customers globally.
What key risks and uncertainties does ICON plc (ICLR) highlight in its forward-looking statements?
ICON highlights risks including dependence on pharmaceutical clients, the need to win and execute projects effectively, industry competition and consolidation, regulatory changes, and exchange-rate, inflation and labor cost pressures, among others referenced in its risk discussions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 333-08704
ICON plc
(Translation of registrant's name into English)
South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Exhibit List
Exhibit Description
99.1 ICON Schedules Second Quarter 2026 Earnings Conference Call
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ICON plc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Date: July 22, 2026 | By: | /s/ Nigel Clerkin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Name: | Nigel Clerkin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Title: | Chief Financial Officer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exhibit 99.1
ICON Schedules Second Quarter 2026 Earnings Conference Call
Dublin, Ireland, July 22, 2026 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the second quarter 2026 after the market closes on Wednesday, July 29, 2026. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 30, 2026 at 8:00am ET.
Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “Events”. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.
About ICON plc
ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,350 employees in 97 locations in 55 countries as at March 31, 2026. For further information about ICON, visit: www.iconplc.com.
Statements included herein which are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, but are not limited to, statements regarding the following: contracted revenue; the repayment of indebtedness; the company's expectations regarding business momentum, market opportunity, demand trends, growth, and commercial performance; and the company's expectations with respect to its long-term value creation and competitive positioning. You can identify many forward-looking statements by words such as “aims,” “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “focused,” “guidance,” “intends,” “look,” “may,” “opportunities,” “plans,” “positions,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. The forward looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, our results could be materially adversely affected. The risks and uncertainties include, but are not limited to, dependence on the pharmaceutical industry and certain clients, the need to regularly win projects and then to execute them efficiently and correctly, the challenges presented by rapid growth, competition and the continuing consolidation of the industry, the impact of market conditions on demand for the company's services, risks related to the company's ability to execute on its commercial strategy and maintain relationships with large pharmaceutical customers, and risks relating to the company's strategic partnerships, the dependence on certain key executives, changes in the regulatory environment, exchange rate fluctuations, inflation and rising labor costs. Please also refer to the section entitled "Risk Factors" of our Annual Report on Form 20-F for the year ended December 31, 2025 for a discussion of some of the principal risks that could adversely affect our business, operations and financial results. The company’s forward-looking statements speak only as of the date of this document or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.
Source: ICON plc
Contact: Kate Haven Vice President Investor Relations +1888 381 7923
ICON/ICLR-G